關鍵詞

CD8+?腫瘤免疫?APOE 阿爾茨海默病 ?CDK4/6 糖基化 阿得貝利單抗 托萊西單抗 全人源單克隆抗體

?

#今日行業(yè)熱點#

①Cancer Cell：A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity

發(fā)現：一個獨特的免疫刺激性1型傳統(tǒng)樹突狀細胞(cDC1)亞群可增強腫瘤中CD8+ T細胞的反應，從而獲得保護性抗腫瘤免疫

DOI: 10.1016/j.ccell.2023.06.008

②Trendsin Neurosciences：Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants

綜述：APOE ε4對衰老的大腦的影響——不止于阿爾茨海默病

DOI: 10.1016/j.tins.2023.06.003

③Cell Reports Medicine ：Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer

聯合靶向RANK通路在管腔型乳腺癌（LBC）中對 CDK4/6 抑制劑的獲得性耐藥

DOI: 10.1016/j.xcrm.2023.101120

④Trends in Immunology：MAdCAM-1: a newly identified microbial 'gut check' for T cells

聚焦：MAdCAM-1，一種新發(fā)現的針對T細胞的微生物“腸道檢查”

DOI: 10.1016/j.it.2023.06.007

⑤Trends in Cancer：Perivascular niches: critical hubs in cancer evolution

綜述：血管周圍生態(tài)位是癌癥進化的關鍵樞紐

10.1016/j.trecan.2023.06.010

⑥Cell Chemical Biology：Chemokine binding to PSGL-1 is controlled by O-glycosylation and tyrosine sulfation

趨化因子與P-選擇素糖蛋白配體-1 (PSGL-1)的結合受O-糖基化和酪氨酸硫酸化(sTyr)控制

DOI: 10.1016/j.chembiol.2023.06.013

⑦PD-L1單抗阿得貝利單抗注射液獲國家藥監(jiān)局臨床試驗默示許可，擬聯合靶向HER3的抗體偶聯藥物（ADC）SHR-A2009用于晚期實體瘤

⑧PCSK9單抗托萊西單抗（IBI306）用于中國高膽固醇血癥患者的Ⅲ期CREDIT-4研究成果見刊，結果積極

⑨創(chuàng)新型靶向腫瘤細胞表面抗原 B7-H3的抗體偶聯藥物（ADC）7MW3711獲NMPA批準針對晚期惡性實體瘤患者開展臨床試驗

⑩靶向CTLA-4的IgG1類全人源單克隆抗體候選藥物BAT4706聯合PD-1單抗BAT1308用于晚期實體瘤的臨床試驗申請獲得批準

科學探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！